Deval Patrick - Global Blood Independent Director
GBTDelisted Stock | USD 68.49 0.00 0.00% |
Director
Mr. Deval. L. Patrick, J.D. is Independent Director of the company. Mr. Patrick joined Bain Capital, LP, where he serves as managing director. From January 2007 to January 2015, Mr. Patrick served as the governor of Massachusetts. Prior to his tenure in government, from 2000 to 2004, Mr. Patrick served as the executive vice president and general counsel at The CocaCola Company. Prior to that, he served as vice president and general counsel at Texaco Inc., from 1998 to 1999. He was a partner in two Boston law firms and, from 1994 to 1997, served as the Assistant Attorney General of the United States for Civil Rights in the Department of Justice. Mr. Patrick received an A.B. in English and American Literature from Harvard College and a J.D. from Harvard Law School since 2015.
Age | 61 |
Tenure | 9 years |
Phone | 650 741-7700 |
Web | www.globalbloodtx.com |
Global Blood Management Efficiency
The company has Return on Asset of (23.82) % which means that on every $100 spent on assets, it lost $23.82. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (124.53) %, meaning that it generated no profit with money invested by stockholders. Global Blood's management efficiency ratios could be used to measure how well Global Blood manages its routine affairs as well as how well it operates its assets and liabilities.The company has 659.05 M in debt with debt to equity (D/E) ratio of 4.92, demonstrating that the company may be unable to create cash to meet all of its financial commitments. Global Blood Therapeutics has a current ratio of 8.35, demonstrating that it is liquid and is capable to disburse its financial commitments when the payables are due. Debt can assist Global Blood until it has trouble settling it off, either with new capital or with free cash flow. So, Global Blood's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Global Blood Therapeutics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Global to invest in growth at high rates of return. When we think about Global Blood's use of debt, we should always consider it together with cash and equity.
Similar Executives
Showing other executives | DIRECTOR Age | ||
Dhanusha Sivajee | HNI Corp | 43 | |
Franklin Miller | Merit Medical Systems | 76 | |
Jemaluddin Kassum | Barrick Gold Corp | 68 | |
Phyllis Wise | Nike Inc | 71 | |
Nolan Karras | Merit Medical Systems | 72 | |
Olivia Kirtley | Barrick Gold Corp | 66 | |
Abbie Smith | HNI Corp | 67 | |
John Rogers | Nike Inc | 62 | |
James Jenkins | HNI Corp | 69 | |
Mary Bell | HNI Corp | 60 | |
Miguel Calado | HNI Corp | 65 | |
Gustavo Cisneros | Barrick Gold Corp | 74 | |
Timothy Cook | Nike Inc | 60 | |
Brett Harvey | Barrick Gold Corp | 67 | |
Michelle Peluso | Nike Inc | 48 | |
Safiatou BaNDaw | Barrick Gold Corp | 64 | |
David Liu | Merit Medical Systems | 43 | |
Ronald Waters | HNI Corp | 69 | |
Michael Stillabower | Merit Medical Systems | 73 | |
Kent Stanger | Merit Medical Systems | 62 | |
Cheryl Francis | HNI Corp | 67 |
Management Performance
Return On Equity | -124.53 | |||
Return On Asset | -23.82 |
Global Blood Therapeutics Leadership Team
Elected by the shareholders, the Global Blood's board of directors comprises two types of representatives: Global Blood inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Global. The board's role is to monitor Global Blood's management team and ensure that shareholders' interests are well served. Global Blood's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Global Blood's outside directors are responsible for providing unbiased perspectives on the board's policies.
Lesley Calhoun, Principal Accounting Officer, Vice President - Finance | ||
Michael Bonney, Director | ||
Stephanie Yao, IR Contact Officer | ||
Myesha Lacy, IR Contact Officer | ||
Mark Perry, Independent Director | ||
Jeffrey Farrow, CFO | ||
Myesha Edwards, IR Contact Officer | ||
Philip Pizzo, Director | ||
Glenn Pierce, Director | ||
Willie Brown, Independent Director | ||
Wendy Yarno, Director | ||
Kevin Starr, Director | ||
Hing Sham, Senior Vice President - Chemistry | ||
Scott Morrison, Director | ||
Deval Patrick, Independent Director | ||
Tricia Suvari, Chief Legal Officer | ||
Peter Radovich, Vice President - Program Leadership and Business Strategy | ||
David Johnson, Chief Commercial Officer | ||
Charles Homcy, Director | ||
Dawn Svoronos, Director | ||
Ted Love, President CEO, Director | ||
Eleanor Ramos, Chief Medical Officer | ||
John Schembri, Vice President of Finance and Administration | ||
Jung Choi, Chief Business and Strategy Officer |
Global Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Global Blood a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | -124.53 | |||
Return On Asset | -23.82 | |||
Profit Margin | (146.82) % | |||
Operating Margin | (137.33) % | |||
Current Valuation | 2.24 B | |||
Shares Outstanding | 64.45 M | |||
Shares Owned By Insiders | 2.72 % | |||
Shares Owned By Institutions | 97.28 % | |||
Number Of Shares Shorted | 9.23 M | |||
Price To Earning | (13.97) X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of labor statistics. Note that the Global Blood Therapeutics information on this page should be used as a complementary analysis to other Global Blood's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Insider Screener module to find insiders across different sectors to evaluate their impact on performance.
Other Consideration for investing in Global Stock
If you are still planning to invest in Global Blood Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Global Blood's history and understand the potential risks before investing.
Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
FinTech Suite Use AI to screen and filter profitable investment opportunities | |
Commodity Directory Find actively traded commodities issued by global exchanges | |
Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum |